Sars Antigen Fia (Screening Test)

Description: Severe acute respiratory syndrome (SARS) is a viral respiratory illness caused by a corona virus called SARS-CoV-1. It was first reported in February 2013 in Asia and the epidemic affected ~ 26 countries and resulted in more than 8000 deaths. Like SARS-CoV-2, SARS-CoV-1 Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-1 and ACE2 may offer some protection against the viral infection. The SARS-CoV-1 Spike Trimer (S1+S2):ACE2 Inhibitor Screening Assay Kit includes the SARS-CoV-1 Spike protein in its native trimeric conformation to provide a more physiologically relevant screen for inhibitors as well as a compatible platform to investigate the specificity of SARS-CoV-2:ACE2 inhibitors._x000D_
The key to this kit is that the SARS-CoV-1 Spike Trimer (S1+S2) protein provides a more biologically relevant model than monomeric Spike RBD protein for the investigation of SARS-CoV-1/host cell interaction. Only a few simple steps on a microtiter plate are required for the assay. First, SARS-CoV-1 Spike Trimer (S1+S2) is coated on a 96-well plate. Next, Biotin-ACE2 is incubated with SARS-CoV-1 Spike Trimer (S1+S2) on the plate. Finally, the plate is treated with Streptavidin-HRP followed by addition of a colorimetric HRP substrate to produce color, which then can be quenched and measured using a UV/Vis microplate reader.

Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The Spike glycoprotein is expressed on the surface of the virus as a trimer. Each Spike protein consists of two subunits, S1 and S2, and the S1 subunit has a receptor binding domain (RBD) which recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer some protection against the viral infection. The SARS-CoV-2 Spike Trimer (S1+S2) :ACE2 Inhibitor Screening Assay Kit includes the Spike protein in its native trimeric conformation to provide a more physiologically relevant screen for inhibitors of the Spike S1:ACE2 interaction._x000D_The SARS-CoV-2 Spike Trimer (S1+S2) :ACE2 Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of this interaction. The key to this kit is that the SARS-CoV-2 Spike Trimer (S1+S2) protein provides a more biologically relevant model than monomeric Spike RBD protein for the investigation of SARS-CoV-2/host cell interaction. Only a few simple steps on a microtiter plate are required for the assay. First, SARS-CoV-2 Spike Trimer (S1+S2) is coated on a 96-well plate. Next, Biotin-ACE2 is incubated with SARS-CoV-2 Spike Trimer (S1+S2) on the plate. Finally, the plate is treated with Streptavidin-HRP followed by addition of a colorimetric HRP substrate to produce color, which then can be quenched and measured using a UV/Vis microplate reader.

Description: The Spike S1 (B.1.1.7 Variant) (SARS-CoV-2):ACE2 Inhibitor Screening Colorimetric Assay Kit is designed for screening and profiling inhibitors of the interaction of ACE2 with the B.1.1.7 variant of the SARS-CoV-2 Spike S1 protein. The key to this kit is the high sensitivity of detection of ACE2-Biotin protein by Streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, Spike S1 B.1.1.7 protein is coated on a 96-well transparent plate. Next, ACE2-Biotin is incubated with Spike S1 variant on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce color, which can then be measured using a UV/Vis spectrophotometer microplate reader. 

Description: The Spike S1 RBD-B.1.351 (SARS-CoV-2): ACE2 Inhibitor Screening Colorimetric Assay Kit is designed for screening and profiling inhibitors of the interaction of ACE2 with the RBD region of the B.1.351 Variant of the SARS-CoV-2 Spike S1 protein.

Description: The Spike S1 (B.1.1.7 Variant) (SARS-CoV-2): ACE2 Inhibitor Screening Chemiluminescence Assay Kit is designed for screening and profiling inhibitors of the interaction of ACE2 with the B.1.1.7 Variant of the SARS-CoV-2 Spike S1 protein. The key to this kit is the high sensitivity of detection of ACE2-Biotin protein by Streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, Spike S1 B.1.1.7 protein is coated on a 96-well transparent plate. Next, ACE2-Biotin is incubated with Spike S1 variant on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can then be measured using a luminometer or microplate reader capable of reding chemiluminescence.

Description: The Spike RBD (SARS-CoV-2) UK variant (N501Y):ACE2 Inhibitor Screening Colorimetric Assay Kit is designed for screening and profiling inhibitors of the interaction of ACE2 with the UK variant (N501Y) of the SARS-CoV-2 Spike RBD protein. The key to this kit is the high sensitivity of detection of ACE2-Biotin protein by Streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, Spike RBD protein UK variant is coated on a 96-well transparent plate. Next, ACE2-Biotin is incubated with Spike RBD UK variant on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce color, which can then be measured using a UV/Vis spectrophotometer microplate reader.

Description: The Spike S1 RBD-B.1.351 (SARS-CoV-2): ACE2 Inhibitor Screening Chemiluminescence Assay Kit is designed for screening and profiling inhibitors of the interaction of ACE2 with the RBD region of the B.1.351 variant of the SARS-CoV-2 Spike S1 protein.

Description: Measures Activated Caspases in intact cells by FACS

Description: The SARS-CoV-2 Spike Trimer (S1+S2) (B.1.351 Variant):ACE2 Inhibitor Screening Colorimetric Assay Kit is designed for screening and profiling inhibitors or neutralizing antibodies of this interaction. The key to this kit is that the SARS-CoV-2 Spike Trimer (S1+S2) (B.1.351 Variant) protein provides a more biologically relevant model than monomeric Spike RBD protein for the investigation of SARS-CoV-2/host cell interaction. Only a few simple steps on a microtiter plate are required for the assay. First, SARS-CoV-2 Spike Trimer (S1+S2) (B.1.351 Variant) is coated on a 96-well plate overnight. Next, the proteins are blocked and pre-incubated with the inhibitor or neutralizing antibody. Upon subsequent incubation with Biotin-ACE2, the plate is treated with Streptavidin-HRP followed by addition of a colorimetric HRP substrate to produce color, which then can be quenched and measured using a UV/Vis microplate reader.

Description: The SARS-CoV-2 Spike Trimer (S1+S2) (B.1.1.7 Variant):ACE2 Inhibitor Screening Colorimetric Assay Kit is designed for screening and profiling inhibitors or neutralizing antibodies of this interaction. The key to this kit is that the SARS-CoV-2 Spike Trimer (S1+S2) (B.1.1.7 Variant) protein provides a more biologically relevant model than monomeric Spike RBD protein for the investigation of SARS-CoV-2/host cell interaction. Only a few simple steps on a microtiter plate are required for the assay. First, SARS-CoV-2 Spike Trimer (S1+S2) (B.1.1.7 Variant) is coated on a 96-well plate overnight. Next, the proteins are blocked and pre-incubated with the inhibitor or neutralizing antibody. Upon subsequent incubation with Biotin-ACE2, the plate is treated with Streptavidin-HRP followed by addition of a colorimetric HRP substrate to produce color, which then can be quenched and measured using a UV/Vis microplate reader.

Description: The Spike S1 RBD (B.1.617.2; Delta Variant) (SARS-CoV-2): ACE2 Inhibitor Screening Colorimetric Assay Kit is designed for screening and profiling inhibitors or neutralizing antibodies of  the interaction between SARS-CoV-2 Spike and human ACE2.  The assay requires only a few steps. First, Spike S1 RBD (B.1.617.2; Delta Variant) (SARS-CoV-2) is coated on a 96-well plate overnight. After blocking, the protein is pre-incubated with the inhibitor or neutralizing antibody. Upon subsequent incubation with Biotin-ACE2, the plate is treated with Streptavidin-HRP followed by addition of a colorimetric HRP substrate to produce color, which can be quenched and measured using a UV/Vis microplate reader.